Ixekizumab provides superior efficacy compared with ustekinumab over 52 weeks of treatment: Results from IXORA-S, a phase 3 study - 13/12/18
, Christopher E.M. Griffiths, MD b, Peter C.M. van de Kerkhof, MD, PhD c, Lluís Puig, MD, PhD d, Yves Dutronc, MD e, Carsten Henneges, PhD e, Martin Dossenbach, MD e, Kristin Hollister, PhD e, Kristian Reich, MD, PhD fAbstract |
Background |
Biologics targeting interleukin 17A (IL-17A) allow for rapid clearance of psoriatic plaques, with a clinically favorable safety profile.
Objectives |
To compare the safety and efficacy of ixekizumab, an IL-17A antagonist, with the safety and efficacy of the IL-12/23 inhibitor ustekinumab through 52 weeks of treatment in the head-to-head trial IXORA-S.
Methods |
Patients were randomized to ixekizumab (n = 136) or ustekinumab (n = 166) and dosed per the approved labels. After 1 year, efficacy was assessed via improvements in Psoriasis Area and Severity Index (PASI) score (with PASI 90 indicating a 90% or greater improvement from baseline PASI score) and a static Physician's Global Assessment (sPGA) response of either 0 or 0 or 1, with dropouts counted as nonresponders. Safety analyses included treatment-emergent adverse events (AEs).
Results |
At week 52, significantly more ixekizumab-treated patients (P < .01) reported PASI 90 (104 [76.5%]), an sPGA response of 0 (72 [52.9%]), or an sPGA response of 0 or 1 (110 [82.1%]) responses than did ustekinumab-treated patients (PASI 90, 98 [59.0%]; sPGA response of 0, 60 [36.1%]; and sPGA response of 0 or 1, 108 [65.1%]). Treatment-emergent AEs, serious AEs, and discontinuation rates were not different between the treatment groups. Injection site reactions occurred more frequently in the ixekizumab-treated group (ixekizumab, 22 [16.3%]; ustekinumab, 2 [1.2%]) (P < .001).
Limitations |
This study was not designed to compare safety end points related to rare events.
Conclusions |
Compared with ustekinumab, ixekizumab showed superior efficacy and comparable safety outcomes through 52 weeks of treatment.
Le texte complet de cet article est disponible en PDF.Key words : biologic, clinical trial, efficacy, ixekizumab, IXORA-S, psoriasis, safety, ustekinumab
Abbreviations used : AE, CI, IL, NNT, NRI, PASI, sPGA, TEAE
Plan
| Funding sources: Supported in full by Eli Lilly and Company, Indianapolis, Indiana. Dr Griffiths is a National Institute for Health Research senior investigator. |
|
| Disclosure: Dr Paul has served as consultant and/or investigator for AbbVie, Amgen, Boehringer, Celgene, Eli Lilly and Company, Janssen, Leo, Novartis, and Pfizer. Dr Griffiths reports grants and personal fees from Eli Lilly and Company during the conduct of the study and grants and personal fees from AbbVie, Janssen, Celgene, Novartis, Pfizer, and GSK-Stiefel; grants from Sandoz, LEO Pharma, MMS, MSD, Sanofi, and Roche; personal fees from Amgen, UCB Pharma, Sun Pharmaceuticals, and MedScape; and, stock/stock options from CG Skin outside the submitted work. Dr van de Kerkhof has served as a consultant for Celgene, Centocor, Allmirall, Amgen, Pfizer, Philips, Abbott, Eli Lilly and Company, Galderma, Novartis, Jansen Cilag, Leo Pharma, Sandoz, and Mitsibishu and has worked as an investigator for Basilea, Pfizer, Eli Lilly and Company, Amgen, Abbvie, Philips Lighting, Jansen Cilag, and Leo Pharma. Dr Puig has been a clinical trial investigator for AbbVie, Amgen, GSK, Janssen, Eli Lilly and Company, MSD, Novartis, Pfizer, Regeneron, and VBL; he has also been a paid adviser/speaker for AbbVie, Amgen, Baxalta, Biogen, Boehringer Ingelheim, Celgene, GSK, Janssen, Leo-Pharma, Eli Lilly and Company, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Sandoz, Sanofi, and VBL. Dr Dutronc, Dr Henneges, Dr Dossenbach, and Dr Hollister are employees of Eli Lilly and Company and receive a salary from and own stock in the company. Dr Reich has served as adviser and/or paid speaker for and/or participated in clinical trials sponsored by AbbVie, Amgen, Biogen, Boehringer Ingelheim Pharma, Celgene, Covagen, Forward Pharma, GlaxoSmithKline, Janssen-Cilag, Leo, Eli Lilly and Company, Medac, Merck Sharp & Dohme Corp, Novartis, Pfizer, Regeneron, Takeda, UCB Pharma, and Xenoport. |
|
| Although the primary objective of this paper is to disclose efficacy and safety for IXORA-S at week 52, data for weeks 0 to 24 are provided for context. The data for weeks 0 to 24 data were previously published in the following article: Reich K, Pinter A, Lacour JP, et al. Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study. Br J Dermatol. 2017;177:1014-1023. |
|
| Reprints not available from the authors. |
Vol 80 - N° 1
P. 70 - janvier 2019 Retour au numéro
Article précédent
- Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study
- Christos C. Zouboulis, Martin M. Okun, Errol P. Prens, Robert Gniadecki, Peter A. Foley, Charles Lynde, Jamie Weisman, Yihua Gu, David A. Williams, Gregor B.E. Jemec
- Apremilast for moderate hidradenitis suppurativa: Results of a randomized controlled trial
- Allard R.J.V. Vossen, Martijn B.A. van Doorn, Hessel H. van der Zee, Errol P. Prens
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?